Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Triamcinolone Acetonide × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 4 Lymphoid 2 Gastrointestinal 2 CNS 2 Thoracic 1 Genitourinary 1 Breast 1

Conditions

Lung Neoplasms 1 Exanthema 1

Interventions

Carboplatin 1138 Cisplatin 869 Pemetrexed 827 pembrolizumab 602 Paclitaxel 595 Docetaxel 532 Gemcitabine 422 Radiotherapy 372 Erlotinib Hydrochloride 367 Bevacizumab 321 Nivolumab 318 Etoposide 291 durvalumab 252 Drug Therapy 229 osimertinib 216 atezolizumab 207 Radiosurgery 186 Gefitinib 177 Vinorelbine 145 130-nm albumin-bound paclitaxel 122 Magnetic Resonance Spectroscopy 118 Ipilimumab 116 Cetuximab 110 tislelizumab 101 anlotinib 101 Topotecan 101 Cyclophosphamide 100 Taxes 98 Irinotecan 95 Albumin-Bound Paclitaxel 90

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00473083 2017-04-04

LUTRAERL

British Columbia Cancer Agency

Phase 2 Completed

150 enrolled 13 charts

Exanthema, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡